Short description
SanBio is a regenerative medicine company.
Description
SanBio is a regenerative medicine company with cell-based products in various stages of research, development, and clinical trials. Its proprietary cell-based product, SB623, is currently in a Phase 2b clinical trial for treatment of chronic motor impairments resulting from stroke with its joint development partner, Sumitomo Dainippon Pharma Co., Ltd., in the United States and Canada. SanBio is also implementing a global Phase 2 clinical trial in the United States and Japan using SB623 for treatment of motor impairment resulting from traumatic brain injury.
Last funding
Nopepepe
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Tokyo, Tokyo, Japan, Asia
Founded on
February 27, 2013
Exited on
April 8, 2015
Went public on
April 8, 2015
Stock symbol
4592
Non-profit?
No
Acquired?
No
Employees count
51-100
Revenue range
$34056 - 789030
Sign in for full access
Investors
Noaccess, Noaccessforu, Noway Youcantaccess, No Way, Cannot Access, No Way
Sign in for full access
Founders
Keita Mori, Mori Keita, Toru Kawanishi, Yoshihiro Kakutani